The table below shows Tango Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$44.36M
-$41.70M
-$37.86M
-$34.91M
-$29.66M
-$13.61M
Capital expenditure
-$2.00K
$51.00K
$195.00K
$620.00K
$1.56M
$165.00K
Investing cash flow
$9.63M
$30.60M
-$11.20M
$31.55M
-$11.72M
$20.61M
Dividends paid
-
-
-
-
TNGX operating cash flow (10-K history)
Tango Therapeutics, Inc. reported operating cash flow of -$138.89M for fiscal year 2025. That is down 5.6% from -$131.50M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from $70.07M (FY 2020) to -$138.89M. Figures come from the company's audited annual reports as filed with the SEC.